fda compounding semaglutide enforcement 2025 news Compound versions of GLP-1 drugs for weight loss halted by Semaglutide Injections and the FDA

Inject 50units (4mg) weekly for clinically effective maintenance dose for sustained weight-loss and metabolic optimization

Results: nejm.org/doi/full/10.10 #ADA2023 Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released phase 2 trial results demonstrating 25% weight loss in half of people with #obesity

Zangabad PS, Vasani RB, Tong Z, Anderson D, Rudd D, Hick CA, et al

In phase 2 trial data published in The New England Journal of Medicine (2023), retatrutide demonstrated substantial weight loss in adults with obesity with some participants losing over 20% of their body weight over approximately 48 weeks

Brand claims regarding effectiveness, mechanism, and manufacturing are attributed to the brand and are not independently verified